BOLT — Bolt Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $12.08m
- -$5.52m
- $7.70m
U.S. STOCKS ON THE MOVE-Workday, Amazon, Accenture
U.S. STOCKS ON THE MOVE-Bolt Biotherapeutics, Sunnova, Jabil
Bolt Biotherapeutics up as FDA grants 'orphan' status to gastric cancer drug
Brief: Bolt Biotherapeutics Receives Orphan Drug Designation For BDC-1001 For Treatment Of Gastric Cancers
Brief: Bolt Biotherapeutics Announces Issuance Of US Patent Covering Dectin-2-Targeting Agonist Antibodies
Bolt Biotherapeutics Inc reports results for the quarter ended in June - Earnings Summary
Bolt Biotherapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Bolt Biotherapeutics Highlights Comprehensive Clinical Data From Phase 1 Dose-Escalation Trial Of Bdc-1001 As Monotherapy And In Combination With Nivolumab In Her2-Expressing Tumors At 2023 Asco Annual Meeting
U.S. STOCKS ON THE MOVE-DXP Enterprises, Holley, Augmedix
U.S. STOCKS ON THE MOVE-Arlo Technologies, Old Republic, Clearmind Medicine
U.S. STOCKS ON THE MOVE-GSK, Fox Corp, First Solar
SVB Securities upgrades Bolt Biotherapeutics to 'outperform'; shares up
Brief: Bolt Biotherapeutics Reports First Quarter 2023 Financial Results And Provides Business Update
Bolt Biotherapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Piedmont Lithium, Walmart, Kilroy Realty
U.S. STOCKS ON THE MOVE-Walmart, JD.Com, Crinetics
U.S. STOCKS ON THE MOVE-Neogen Corp, Freight Technologies, Philip Morris
Bolt Biotherapeutics gains on promising data from cancer therapy trial
Bolt Biotherapeutics gains on promising data from cancer therapy trial